HTATIP2 | bioCADDIE Data Discovery Index
Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
Displaying 20 of 21 results for "HTATIP2"
i
  1. CC3(TIP30)Crystal Structure PDB

    ID: PDB:2BKA

    Description: TAT-INTERACTING PROTEIN TIP30

  2. Exogenous expression of CC3/TIP30 in U373 cells with or without UV treatment BioProject

    ID: PRJNA124849

    Keywords: Transcriptome or Gene expression

    Access Type: download

  3. Crystal structure of a tat-interacting protein homologue (htatip2, aw111545, cc3, tip30) from mus musculus at 2.30 A resolution PDB

    ID: PDB:2FMU

    Description: HIV-1 tat interactive protein 2, 30 ...

  4. Microbacterium paludicola strain:CC3 : Microbacterium paludicola strain:CC3 Genome sequencing BioProject

    ID: PRJNA353763

    Keywords: Genome sequencing

    Access Type: download

    dataset.description: whole genome of strain Microbacterium paludicola CC3 was sequenced to understand genetic basis of biosynthesis of polysaccharide bioflocculant...
  5. HTAI2_PONPY UniProt:Swiss-Prot

    ID: A2T7G9

    Description: Removed Oxidoreductase HTATIP2 NADP Proton acceptor Substrate N-acetylalanine

  6. Exogenous expression of CC3/TIP30 in U373 cells with or without UV treatment GEMMA

    ID: 2463

    Keywords: functional genomics

    Description: The pro-apoptotic protein CC3/TIP30 has an unusual cellular function as an inhibitor of nucleocytoplasmic trans...

  7. HTAI2_GORGO UniProt:Swiss-Prot

    ID: A1YER2

    Description: Removed Oxidoreductase HTATIP2 NADP Proton acceptor Substrate N-acetylalanine

  8. HTAI2_PANPA UniProt:Swiss-Prot

    ID: A1YFX9

    Description: Removed Oxidoreductase HTATIP2 NADP Proton acceptor Substrate N-acetylalanine

  9. RNA-seq analysis of contextual fear conditioning BioProject

    ID: PRJNA267703

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: control for variations due to circadian rhythms (CC3). The protocol was repeated over the course of 5 days to obtain 9 animals (2 hippocampi) per group, so that 5 independent FC experiments were represented in each time point and all animals for each group were dissected at the exactly the same time of day....
  10. RNA-seq analysis of contextual fear conditioning ArrayExpress

    ID: E-GEOD-63412

    Description: control for variations due to circadian rhythms (CC3). The protocol was repeated over the course of 5 days to obtain 9 animals (2 hippocampi) per group, so that 5 independent FC experiments were represented in each time point and all animals for each group were dissected at the exactly the same time of day....

  11. Transcriptomic dysregulation in aggressive and malignant prolactin tumours ArrayExpress

    ID: E-GEOD-22812

    Description: ssified as non-invasive (NI; n=5), invasive (I; n=2) or aggressive-invasive (AI; n=6). Each tumour showed copy number alterations which appeared to be varied and discrete in the NI and I tumour groups, and more numerous and extensive in the AI tumour group. Allelic loss within the p arm region of chromosome 11 was detected in five of the AI tumours. This region contains the cytobands 11p15.2, 11p15.1, 11p14.3, 11p14.2, 11p14.1, 11p13, 11p12 and 11p11.2. Furthermore, an allelic loss in the 11q arm was also observed in three of these five tumours, which were considered malignant based on...

  12. Transcriptomic dysregulation in aggressive and malignant prolactin tumours BioProject

    ID: PRJNA153907

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: ssified as non-invasive (NI; n=5), invasive (I; n=2) or aggressive-invasive (AI; n=6). Each tumour showed copy number alterations which appeared to be varied and discrete in the NI and I tumour groups, and more numerous and extensive in the AI tumour group. Allelic loss within the p arm region of chromosome 11 was detected in five of the AI tumours. This region contains the cytobands 11p15.2, 11p15.1, 11p14.3, 11p14.2, 11p14.1, 11p13, 11p12 and 11p11.2. Furthermore, an allelic loss in the 11q arm was also observed in three of these five tumours, which were considered malignant based on...
  13. Genomic alterations of chromosome 11 induce transcriptomic dysregulation in aggressive and malignant prolactin tumours ArrayExpress

    ID: E-GEOD-22615

    Description: as aggressive with a high proliferation rate and short post-operative time to recurrence and 0.2% metastasize. The molecular events associated to the progression of the pituitary tumor toward an aggressive and malignant phenotype is still unresolved. To bring new hypothesis on signaling pathwa...

  14. Genomic alterations of chromosome 11 induce transcriptomic dysregulation in aggressive and malignant prolactin tumours BioProject

    ID: PRJNA153905

    Keywords: Variation

    Access Type: download

    dataset.description: as aggressive with a high proliferation rate and short post-operative time to recurrence and 0.2% metastasize. The molecular events associated to the progression of the pituitary tumor toward an aggressive and malignant phenotype is still unresolved. To bring new hypothesis on signaling pathwa...
  15. NCP3_COPCM UniProt:Swiss-Prot

    ID: P83454

    Description: Alkaline protease Cc3

  16. Efficacy of carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple negative breast c... ArrayExpress

    ID: E-GEOD-55399

    Description: -damage (?-H2AX) and apoptosis (cleaved-Caspase-3(cC3)) were assessed via IHC of IC tumors. Gene expression of BRCA-mutant IC tumors was measured. Results: Carboplatin+/-ABT888 significantly improved survival in BRCA-mutant IC models compared to control, but did not improve survival in BRCA-wild-type IC models. Carboplatin+ABT888 revealed a modest survival advantage versus Carboplatin in BRCA-mutant models. ABT888 yielded a marginal survival benefit in the MDA-MB-436 but not in the SUM149 model. BRCA-mutant SUM149 expression of ?-H2AX and cC3 proteins was elevated in all treatment groups compared to Control, while BRCA-wild-type MDA-MB-468 cC3 expression did not increase with treatment. Carboplatin treatment induced common gene expression changes in BRCA-mutant models.Conclusions: Carboplatin+/-ABT888 improves survival in BRCA-mutant IC TNBC models with corresponding DNA damage and gene expression changes. Combination therapy represents a promising treatment strategy for patients with TNBC brain metastases warranting further clinica...

  17. Transcriptomic dysregulation in aggressive and malignant prolactin tumours OmicsDI

    ID: E-GEOD-22812

    Date Released: 06-26-2012

    Description: ssified as non-invasive (NI; n=5), invasive (I; n=2) or aggressive-invasive (AI; n=6). Each tumour showed copy number alterations which appeared to be varied and discrete in the NI and I tumour groups, and more numerous and extensive in the AI tumour group. Allelic loss within the p arm region of chromosome 11 was detected in five of the AI tumours. This region contains the cytobands 11p15.2, 11p15.1, 11p14.3, 11p14.2, 11p14.1, 11p13, 11p12 and 11p11.2. Furthermore, an allelic loss in the 11q arm was also observed in three of these five tumours, which were considered malignant based on...

  18. Genomic alterations of chromosome 11 induce transcriptomic dysregulation in aggressive and malignant prolactin tumours OmicsDI

    ID: E-GEOD-22615

    Date Released: 01-27-2013

    Description: as aggressive with a high proliferation rate and short post-operative time to recurrence and 0.2% metastasize. The molecular events associated to the progression of the pituitary tumor toward an aggressive and malignant phenotype is still unresolved. To bring new hypothesis on signaling pathwa...

  19. Efficacy of carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple negative breast c... OmicsDI

    ID: E-GEOD-55399

    Date Released: 05-22-2015

    Description: -damage (?-H2AX) and apoptosis (cleaved-Caspase-3(cC3)) were assessed via IHC of IC tumors. Gene expression of BRCA-mutant IC tumors was measured. Results: Carboplatin+/-ABT888 significantly improved survival in BRCA-mutant IC models compared to control, but did not improve survival in BRCA-wild-type IC models. Carboplatin+ABT888 revealed a modest survival advantage versus Carboplatin in BRCA-mutant models. ABT888 yielded a marginal survival benefit in the MDA-MB-436 but not in the SUM149 model. BRCA-mutant SUM149 expression of ?-H2AX and cC3 proteins was elevated in all treatment groups compared to Control, while BRCA-wild-type MDA-MB-468 cC3 expression did not increase with treatment. Carboplatin treatment induced common gene expression changes in BRCA-mutant models.Conclusions: Carboplatin+/-ABT888 improves survival in BRCA-mutant IC TNBC models with corresponding DNA damage and gene expression changes. Combination therapy represents a promising treatment strategy for patients with TNBC brain metastases warranting further clinica...

  20. Efficacy of carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple negative breast c... BioProject

    ID: PRJNA239689

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: -damage (?-H2AX) and apoptosis (cleaved-Caspase-3(cC3)) were assessed via IHC of IC tumors. Gene expression of BRCA-mutant IC tumors was measured. Results: Carboplatin+/-ABT888 significantly improved survival in BRCA-mutant IC models compared to control, but did not improve survival in BRCA-wild-type IC models. Carboplatin+ABT888 revealed a modest survival advantage versus Carboplatin in BRCA-mutant models. ABT888 yielded a marginal survival benefit in the MDA-MB-436 but not in the SUM149 model. BRCA-mutant SUM149 expression of ?-H2AX and cC3 proteins was elevated in all treatment groups compared to Control, while BRCA-wild-type MDA-MB-468 cC3 expression did not increase with treatment. Carboplatin treatment induced common gene expression changes in BRCA-mutant models.Conclusions: Carboplatin+/-ABT888 improves survival in BRCA-mutant IC TNBC models with corresponding DNA damage and gene expression changes. Combination therapy represents a promising treatment strategy for patients with TNBC brain metastases warranting further clinica...

Displaying 20 of 21 results for "HTATIP2"